Table 1.
Ongoing clinical trials of venetoclax triplet combination therapies.
| Combination Therapy | National Clinical Trial Number |
|---|---|
| Venetoclax + Azacitidine + Lintuzumab | NCT03932318 |
| Venetoclax + Azacitidine + Siremadlin | NCT05155709 |
| Venetoclax + Azacitidine + SL-401 | NCT03113643 |
| Venetoclax + Azacitidine + Tamibarotene | NCT04905407 |
| Venetoclax + SNDX-5613 + ASTX727 | NCT05360160 |
| Venetoclax + Azacitidine + Pembrolizumab | NCT04284787 |
| Venetoclax + Decitabine + Quizartinib | NCT03661307 |
| Venetoclax + Uproleselan + Azacitidine | NCT04964505 |
| Venetoclax + ASTX27 + Gilteritinib | NCT05010122 |
| Venetoclax + Azacitidine + Trametinib | NCT04487106 |
| Venetoclax + Azacitidine + Ivosidenib | NCT03471260 |
| Venetoclax + Decitabine + Gilteritinib | NCT03013998 |
| Venetoclax + Azacitidine + Magrolimab | NCT05079230 |
| Venetoclax + Intensive chemotherapy | NCT04801797 |
| Venetoclax + Azacitidine + Evorpacept | NCT04755244 |
| Venetoclax + Azacitidine + Revumenib | NCT05761171 |
| Venetoclax + Azacitidine + Pevonedistat | NCT04266795 |
| Venetoclax + Azacitidine + CC-90011 | NCT04748848 |
| Venetoclax + Azacitidine + IMGN632 | NCT04086264 |